$CYDY From what I've seen, when results are unblinded, like so many prior therapeutics, the data is released. Of course, for the most part, nearly every other prior therapeutic has not hit it's primary endpoint. Nonetheless, I'm unaware of any prior MAB/therapeutic being unable to disclose results because it was in confidential negotiations with all these regulatory bodies (price/distribution/etc.?). My point is that, if CYDY didn't hit it's endpoint and prove significant efficacy with the unblinding of it's data, why would these regulatory agencies be negotiating with them? If the data wasn't solid, these regulatory agencies/decision makers would have no reason to be negotiating with CYDY at all? I don't see any other rationale explanation as to why the FDA, etc., would be negotiating about a drug they're not interested. Ultimate conclusion: Holy shit this is happening!
3
15
15 Likes